Loading
A phase 3 trial testing TAR-210 in bladder & urothelial cancer, now recruiting.
A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer is a phase 3 interventional study registered as NCT06919965, led by Janssen Research & Development, and recruiting on the registry. Official title: A Phase 3, Randomised, Open-label, Multicenter Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Investigator's Choice of Intravesical Chemotherapy in Participants With High-risk Non-muscle-invasive Bladder Cancer With Susceptible FGFR Alterations Who Had Received Intravesical Bacillus Calmette-Guérin (BCG). Planned enrolment is 220 participants (estimated). The study started in 2025-09-10 and primary completion is expected in 2028-04-06. No results have been posted on ClinicalTrials.gov.
Shares TAR-210, Non-muscle-invasive bladder cancer, Johnson & Johnson, Bladder & urothelial cancer.
Shares Non-muscle-invasive bladder cancer, Johnson & Johnson, Bladder & urothelial cancer.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer.